Generic versions of Teva's multi-billion-dollar per year multiple sclerosis drug Copaxone (glatiramer) have arrived, but a closer look at which competitor might win the coveted 180-day exclusivity ...

A new study by researchers in the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential drug targets for the treatment of multiple sclerosis. The study may pave the ...

Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...

BOSTON — A new generic version of glatiramer acetate for multiple sclerosis (MS) has shown similar results to the branded agent (Copaxone, Teva Pharmaceuticals) in terms of reduction in lesions on ...

The Commission opened proceedings against Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals Europe B.V. in March 2021 under Article 102 TFEU, following dawn raids in October 2019; a ...

BOSTON -- A copycat version of the multiple sclerosis drug Copaxone, known generically as glatiramer acetate, performed similarly to the original product in a head-to-head trial, paving the way for it ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

San Antonio’s H-E-B and other major retailers have teamed up to wage legal battles on both coasts against pharmaceutical companies for allegedly monopolizing the market for certain prescription drugs.

Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial in the most common form of the disease. The Swiss pharmaceutical company said Monday that ...